Dynavax Technologies Corp (NASDAQ:DVAX)

15.95
Delayed Data
As of Jun 20
 +0.05 / +0.31%
Today’s Change
8.15
Today|||52-Week Range
24.45
-14.71%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.2B

Company Description

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.

Contact Information

Dynavax Technologies Corp.
2929 Seventh Street
Berkeley California 94710-2753
P:(510) 848-5100
Investor Relations:
(510) 665-7269

Employees

Shareholders

Other institutional44.08%
Mutual fund holders35.58%
Individual stakeholders0.82%

Top Executives

Eddie J. GrayChief Executive Officer & Director
David F. NovackSenior Vice President-Operations & Quality
Michael S. OstrachChief Financial & Business Officer, Senior VP
Robert L. CoffmanChief Scientific Officer & Senior Vice President
Robert JanssenChief Medical Officer & SVP-Regulatory Affairs